istock-659112420_kate_sept2004

kate_sept2004 / iStockphoto.com

26 October 2018Americas

Generic competition: when one door closes, another opens

For consumers, the prospect of drugs going off-patent may well be a blessing. But for the pharmaceutical companies behind the branded medication, the onslaught of generic competition is seemingly far from positive.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

Sandoz wins $137.2m payout for lost profits in generic launch

Dexcom suffers second patent revocation at hands of UPC

Sanofi signs global rights deal to develop rare cancer therapy

WBD to merge with firm to create ‘powerhouse’ practice

Novo Nordisk files fresh lawsuits to intercept Wegovy generics

AstraZeneca unit draws line under Samsung dispute